Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia

• প্রধান লেখক: N. A. Avxentyev (লেখক), Yu. V. Makarova (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: IRBIS LLC, 2023-11-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods. The comparators included "dabrafenib + trametinib" combi...